The Middle East generic drugs market size was estimated at USD 29.36 billion in 2025 and is projected to be worth around USD 51.60 billion by 2035, growing at a CAGR of 5.8% from 2026 to 2035. The launch of generic drugs in the Middle East market helps healthcare systems to save money on increasing costs of medicines, driven by the integral role of lower prices in reducing budget pressures while offering quality treatments.

Middle East Generic Drugs Market Statical Scope

Research studies implied that the Middle East and North Africa region experiences a surge in non-communicable diseases such as diabetes, cancer, and heart disease, followed by increased healthcare demands, lifestyle changes, and increased life expectancy. The governments across the Middle East region have introduced significant healthcare reforms for the pharmaceutical industry. The key factors driving the pharmaceutical industry across the Middle East and North Africa region are the rising healthcare demands, government reforms, technological advancements, improved supply chain management , price controls, improved regulatory environment, momentous growth of generics and biosimilars , and strategic partnerships.

Middle East Generic Drugs Market Share, By Drug Type, 2025 (%)

• Simple Generics- The simple generics segment held a considerable revenue share of 62%, owing to the common applications of simple generic drugs in treating pain, fever, heart health, blood pressure, digestive health, diabetes, allergy, infections, and respiratory issues.
• Biosimilars- The biosimilars segment is seen to hold a share of 14%, accelerated by the similar clinical safety and efficacy as that of original brand-name drugs.

Middle East Generic Drugs Market Share, By Therapeutic Area, 2025 (%)

• Cardiovascular- The cardiovascular segment is seen to grow and expand with a share of 27%, supported by the innovative generic drug classes for treating cardiovascular issues, including anticoagulants, beta-blockers, lipid-lowering medications, etc.
• Central Nervous System (CNS)- The central nervous system (CNS) segment is expanding with a share of 16%, due to the growing awareness and diagnosis of neurological conditions.

Middle East Generic Drugs Market Share, By Route of Administration, 2025 (%)

• Oral Solids- The oral solids segment held a share of 54%, owing to the advantages of oral solids, including accurate dose, high stability, ease of manufacturing at scale, and high patient convenience.
• Inhalables- The inhalables segment is growing with a share of 10%, supported by their heavy use in treating respiratory conditions, but limited by specific application areas.

Middle East Generic Drugs Market Share, By Distribution Channel, 2025 (%)

• Retail Pharmacies- The retail pharmacies segment led the market with a share of 48%, owing to a rapidly expanding chain of retail pharmacies, focusing on affordable healthcare.
• Specialty Pharmacies- The specialty pharmacies segment occupied a share of 12%, driven by the increasing demand for complex and high-value medications.

Top Companies in the Middle East Generic Drugs Market

• Sandoz
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC

Segments Covered in the Report

By Drug Type

• Simple Generics
• Specialty Generics
• Biosimilars
• Complex Generics

By Therapeutic Area

• Cardiovascular
• Oncology
• Anti-Infective
• Central Nervous System
• Endocrine/Metabolic
• Respiratory
• Others

By Route of Administration

• Oral
• Injectable
• Topical
• Inhalable
• Other Route of Administration

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Other Distribution Channel